• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国国家联合委员会与《医师案头参考手册》推荐的抗高血压药物的药物不良反应、依从性及初始剂量

Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference.

作者信息

Cohen J S

机构信息

Department of Family and Preventive Medicine, University of California-San Diego, La Jolla, USA.

出版信息

Arch Intern Med. 2001 Mar 26;161(6):880-5. doi: 10.1001/archinte.161.6.880.

DOI:10.1001/archinte.161.6.880
PMID:11268233
Abstract

BACKGROUND

Compliance problems are common causes of the inadequate treatment of hypertension, with 16% to 50% of patients quitting treatment within 1 year. Dose-related adverse drug events (ADEs) frequently cause compliance problems, and many ADEs occur with the initial doses of antihypertensive drugs. Thus, it is an established tenet to initiate antihypertensive therapy at low doses to avoid ADEs that diminish patients' quality of life and reduce compliance. However, what are the lowest effective doses of antihypertensive drugs?

OBJECTIVE

To compare the initial doses recommended in the Physicians' Desk Reference (PDR) with those recommended by the Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI).

METHODS

Review of the latest JNC VI report (1997) and the 1999 and 2000 editions of the PDR and the medical literature.

RESULTS

The JNC VI recommends substantially lower initial doses for 23 (58%) of 40 drugs, compared with the PDR. In addition, for 37 (82%) of 45 drugs, PDR guidelines do not suggest lower initial doses for old or frail patients than for younger adults.

CONCLUSIONS

Although the PDR is the drug reference most used by physicians, it does not reflect the lowest initial doses that are recommended by the JNC VI for many of the most prescribed antihypertensive drugs. Because avoidance of ADEs is essential to maintaining compliance with antihypertensive therapy, and because many antihypertensive ADEs are dose related, physicians must know the very lowest, effective, least ADE-prone doses. Patients and physicians would benefit by establishing mechanisms to make this information readily available to all practicing physicians.

摘要

背景

依从性问题是高血压治疗不充分的常见原因,16%至50%的患者在1年内停止治疗。与剂量相关的药物不良事件(ADEs)经常导致依从性问题,许多ADEs发生在抗高血压药物的初始剂量时。因此,以低剂量开始抗高血压治疗以避免降低患者生活质量并降低依从性的ADEs是既定原则。然而,抗高血压药物的最低有效剂量是多少?

目的

比较《医师案头参考》(PDR)中推荐的初始剂量与美国国家高血压检测、评估和治疗联合委员会第六次报告(JNC VI)推荐的初始剂量。

方法

查阅最新的JNC VI报告(1997年)以及1999年和2000年版的PDR及医学文献。

结果

与PDR相比,JNC VI对40种药物中的23种(58%)推荐了低得多的初始剂量。此外,对于45种药物中的37种(82%),PDR指南未建议老年或体弱患者的初始剂量低于年轻成年人。

结论

尽管PDR是医生最常用的药物参考,但它并未反映JNC VI对许多最常用抗高血压药物推荐的最低初始剂量。由于避免ADEs对于维持抗高血压治疗的依从性至关重要,并且由于许多抗高血压ADEs与剂量相关,医生必须了解最低、有效、最不易发生ADEs的剂量。建立机制使所有执业医生都能方便获取这些信息,将使患者和医生受益。

相似文献

1
Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference.美国国家联合委员会与《医师案头参考手册》推荐的抗高血压药物的药物不良反应、依从性及初始剂量
Arch Intern Med. 2001 Mar 26;161(6):880-5. doi: 10.1001/archinte.161.6.880.
2
Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.《医师案头参考》与医学文献之间的剂量差异及其在与剂量相关的药物不良事件高发率中可能发挥的作用。
Arch Intern Med. 2001 Apr 9;161(7):957-64. doi: 10.1001/archinte.161.7.957.
3
Discrepant antihypertensive dose recommendations.不一致的降压药物剂量推荐。
Clin Exp Hypertens. 2006 Feb;28(2):171-80. doi: 10.1080/10641960500468615.
4
Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.患者报告的对第六届全国高血压预防、检测、评估与治疗联合委员会指南的依从性。
Pharmacotherapy. 2001 Jul;21(7):828-41. doi: 10.1592/phco.21.9.828.34557.
5
Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines.医疗补助计划开处方者对《美国国家联合委员会第六版高血压治疗指南》的依从性。
Ann Pharmacother. 2002 Oct;36(10):1505-11. doi: 10.1345/aph.1A451.
6
Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine.基层医疗医生自我报告的高血压治疗实践:血压阈值、药物选择以及指南和循证医学的作用。
Arch Intern Med. 2000;160(15):2281-6. doi: 10.1001/archinte.160.15.2281.
7
Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited.
Am J Hypertens. 1999 Dec;12(12 Pt 3):225S-230S. doi: 10.1016/s0895-7061(99)00102-8.
8
Antihypertensive Drug Therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year.抗高血压药物治疗。美国国家联合委员会(JNC)标准对第一年处方模式和患者状况的影响。
Am J Hypertens. 1996 May;9(5):413-8. doi: 10.1016/0895-7061(95)00438-6.
9
Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy.意大利高血压管理模式:一项关于抗高血压治疗的药物流行病学调查结果。意大利抗高血压治疗药物流行病学调查科学委员会
J Hypertens. 2000 Nov;18(11):1691-9. doi: 10.1097/00004872-200018110-00023.
10
Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.次优药物使用的经济学:使用美国国家联合委员会(JNC)推荐药物治疗单纯性原发性高血压的成本节约
Am J Manag Care. 2003 Aug;9(8):529-36.

引用本文的文献

1
High Intensity Interval Training and Arterial Hypertension: Quality of Reporting.高强度间歇训练与动脉高血压:报告质量
Sports Med Int Open. 2025 Feb 12;9:a24939466. doi: 10.1055/a-2493-9466. eCollection 2025.
2
Inhibition of soluble epoxide hydrolase by natural isothiocyanates.天然异硫氰酸酯对可溶性环氧化物水解酶的抑制作用。
Biochem Biophys Res Commun. 2024 Sep 17;725:150261. doi: 10.1016/j.bbrc.2024.150261. Epub 2024 Jun 12.
3
Genomic markers associated with successful treatment of hypertension with lisinopril: A pilot study.
与赖诺普利治疗高血压成功相关的基因组标志物:一项初步研究。
Int J Clin Pharmacol Ther. 2021 Jul;59(7):506-510. doi: 10.5414/CP203910.
4
Blood Pressure Changes in 1610 Subjects With and Without Antihypertensive Medication During Long-Term Fasting.1610 例接受和不接受抗高血压药物治疗的受试者在长期禁食期间的血压变化。
J Am Heart Assoc. 2020 Dec;9(23):e018649. doi: 10.1161/JAHA.120.018649. Epub 2020 Nov 23.
5
The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19.血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体阻滞剂对2019冠状病毒病患者住院时间和生存率的影响。
Int J Cardiol Heart Vasc. 2020 Dec;31:100660. doi: 10.1016/j.ijcha.2020.100660. Epub 2020 Oct 15.
6
TRPV1 (Transient Receptor Potential Vanilloid 1) Cardiac Spinal Afferents Contribute to Hypertension in Spontaneous Hypertensive Rat.瞬时受体电位香草酸 1 型(TRPV1)心脏脊神经传入纤维参与自发性高血压大鼠的高血压形成。
Hypertension. 2019 Oct;74(4):910-920. doi: 10.1161/HYPERTENSIONAHA.119.13285. Epub 2019 Aug 19.
7
Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon.上市后较低剂量处方及其影响因素。
PLoS One. 2019 Jun 14;14(6):e0218534. doi: 10.1371/journal.pone.0218534. eCollection 2019.
8
The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂有效性和安全性的药物基因组学和代谢组学预测因子。
Cardiovasc Drugs Ther. 2017 Aug;31(4):471-482. doi: 10.1007/s10557-017-6733-2.
9
The Malaysian Medication Adherence Scale (MALMAS): Concurrent Validity Using a Clinical Measure among People with Type 2 Diabetes in Malaysia.马来西亚药物依从性量表(MALMAS):在马来西亚2型糖尿病患者中使用临床测量方法进行的同时效度研究
PLoS One. 2015 Apr 24;10(4):e0124275. doi: 10.1371/journal.pone.0124275. eCollection 2015.
10
Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.中国抗肿瘤药物的超说明书及非NCCN指南用药情况
Iran J Public Health. 2013 May 1;42(5):472-9. Print 2013.